Y Pang1, Y-Z Ruan1, J Zhao1, C Chen1, C-H Xu1, W Su1, S-T Huan2, R-Z Li1, Y-L Zhao1, D P Chin2, L-X Wang1. 1. National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China. 2. Bill & Melinda Gates Foundation, China Office, Beijing, China.
Abstract
OBJECTIVE: A retrospective clinical trial to evaluate treatment outcomes in adults with smear-positive tuberculosis (TB) and discordant rifampicin (RMP) resistance results. DESIGN: A total of 2156 smear-positive TB patients underwent both conventional and Genechip drug susceptibility testing (DST) for RMP resistance. All 49 patients with discordant results treated with either a first-line or second-line regimen were analysed. RESULTS: Of 30 Type I cases (Genechip-resistant, conventional DST-susceptible) receiving the first-line regimen, 4 had a favourable outcome and 5 failed treatment. The 21 remaining Type I cases were treated with the second-line regimen, of whom 18 had a favourable outcome. Second-line regimen thus resulted in significantly more favourable outcomes than first-line treatment (P = 0.032). Among Type II cases (Genechip-susceptible, conventional DST-resistant), 13/19 received the first-line regimen, and 7 had a favourable outcome. The six Type II cases treated with the second-line regimen all had favourable outcomes. CONCLUSION: Patients with discordant RMP DST results who receive second-line regimens may have a better clinical response than those treated with the first-line regimen. Patients infected with fluoroquinolone-resistant Mycobacterium tuberculosis strains were observed to have a significantly higher treatment failure rate.
OBJECTIVE: A retrospective clinical trial to evaluate treatment outcomes in adults with smear-positive tuberculosis (TB) and discordant rifampicin (RMP) resistance results. DESIGN: A total of 2156 smear-positive TB patients underwent both conventional and Genechip drug susceptibility testing (DST) for RMP resistance. All 49 patients with discordant results treated with either a first-line or second-line regimen were analysed. RESULTS: Of 30 Type I cases (Genechip-resistant, conventional DST-susceptible) receiving the first-line regimen, 4 had a favourable outcome and 5 failed treatment. The 21 remaining Type I cases were treated with the second-line regimen, of whom 18 had a favourable outcome. Second-line regimen thus resulted in significantly more favourable outcomes than first-line treatment (P = 0.032). Among Type II cases (Genechip-susceptible, conventional DST-resistant), 13/19 received the first-line regimen, and 7 had a favourable outcome. The six Type II cases treated with the second-line regimen all had favourable outcomes. CONCLUSION:Patients with discordant RMP DST results who receive second-line regimens may have a better clinical response than those treated with the first-line regimen. Patients infected with fluoroquinolone-resistant Mycobacterium tuberculosis strains were observed to have a significantly higher treatment failure rate.
Authors: Martin Hunt; Brice Letcher; Kerri M Malone; Giang Nguyen; Michael B Hall; Rachel M Colquhoun; Leandro Lima; Michael C Schatz; Srividya Ramakrishnan; Zamin Iqbal Journal: Genome Biol Date: 2022-07-05 Impact factor: 17.906
Authors: Neha S Shah; S Y Grace Lin; Pennan M Barry; Yi-Ning Cheng; Gisela Schecter; Ed Desmond Journal: Open Forum Infect Dis Date: 2016-08-24 Impact factor: 3.835
Authors: Nomonde R Mvelase; Melendhran Pillay; Wilbert Sibanda; Jacqueline N Ngozo; James C M Brust; Koleka P Mlisana Journal: Open Forum Infect Dis Date: 2019-02-12 Impact factor: 3.835